Clinical Trials for Pancreas Cancer

Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic pancreatic adenocarcinoma are subtyped by PurIST: basal-like tumors receive bi-weekly gemcitabine/nab‑paclitaxel plus low‑dose erlotinib (EGFR TKI) with dose optimization, while classical tumors receive standard oxaliplatin-based triplet chemotherapy (FOLFIRINOX or NALIRIFOX). Eligible patients have ECOG 0–1, measurable disease, no prior systemic therapy for PDAC, and tissue available for PurIST testing.

ClinicalTrials.gov ID: NCT06483555

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with well/moderately differentiated, metastatic, unresectable, somatostatin receptor–positive pancreatic NETs (ECOG 0–2) who are PRRT- and sunitinib-naïve, allowing prior SSA and up to one prior systemic therapy. Investigates combination of lutetium Lu 177 dotatate PRRT and sunitinib (multi–TKI targeting VEGFR/PDGFR) to define safety/MTD and assess preliminary efficacy.

ClinicalTrials.gov ID: NCT05687123

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with biopsy-proven locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–2, minimal prior therapy allowed) receive standard multiagent chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation of the primary tumor and pembrolizumab, an anti–PD-1 antibody. Aims to test whether local ablation can enhance immune priming and systemic activity of PD-1 blockade alongside chemotherapy.

ClinicalTrials.gov ID: NCT06831136

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors refractory to standard therapy (mCRPC, metastatic breast cancer subtypes including TNBC, HR+/HER2− or HER2-low, HR−/HER2+, NSCLC, CRC, PDAC) receive MBRC-201, an investigational antibody‑drug conjugate targeting a tumor-associated antigen and delivering a likely topoisomerase I inhibitor payload. Requires ECOG 0–2 and measurable disease in expansion/Phase 2; excludes active CNS disease and prior camptothecin‑payload ADCs in later phases.

ClinicalTrials.gov ID: NCT07145255

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic pancreatic ductal adenocarcinoma harboring a KRASG12D mutation after prior cytotoxic therapy receive IV mesenchymal stromal cell–derived exosomes loaded with KRASG12D siRNA (iExosomes) on days 1, 4, and 10 of 14‑day cycles, up to 3 cycles with possible extension. The investigational therapy delivers siRNA via exosomes to degrade KRASG12D mRNA and suppress downstream MAPK signaling; eligibility requires ECOG 0–1 and adequate organ function, with treated/stable brain metastases permitted.

ClinicalTrials.gov ID: NCT03608631

Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with pancreatic ductal adenocarcinoma limited to the peritoneum (PCI ≤8, ECOG 0–1), including resectable/borderline/locally advanced disease and select patients with up to 4 months of prior FOLFIRINOX/NALIRIFOX without progression, receive intraperitoneal paclitaxel (microtubule stabilizer) on days 1 and 8 plus systemic NALIRIFOX (5-FU/leucovorin, liposomal irinotecan [topoisomerase I inhibitor], oxaliplatin) on day 1 of 14-day cycles up to 12 cycles. The trial evaluates safety and signals of efficacy, with goals of peritoneal disease control and potential conversion to surgery.

ClinicalTrials.gov ID: NCT07030283

A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with newly diagnosed, measurable metastatic pancreatic ductal adenocarcinoma and good performance status (ECOG 0–1) who have not received prior chemotherapy for metastatic disease (prior adjuvant/perioperative gemcitabine allowed if completed ≥6 months before metastasis). Treatment is single-arm pegcetacoplan (a proximal complement C3 inhibitor) added to first-line mFOLFIRINOX given q14 days for up to 8 cycles, evaluating safety plus preliminary antitumor and thromboembolism-reduction signals.

ClinicalTrials.gov ID: NCT07214298

Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Randomizes adults with ctDNA-negative, oligometastatic stage IV foregut adenocarcinoma after ≥4 months of non-progressing systemic therapy to definitive local cytoreduction of all known primary/metastatic sites versus continued standard systemic therapy. Local treatment may include surgery, radiation, ablation, or embolization, with serial tumor-informed Signatera ctDNA monitoring in both arms.

ClinicalTrials.gov ID: NCT07282912

A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ACT Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine (ACT-IOP-003) Once Weekly or Twice Weekly Following First-Line Systemic Chemotherapy in Participants With Nonresectable Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1, nonmetastatic borderline/locally advanced pancreatic adenocarcinoma confirmed unresectable after prior FOLFIRINOX or gemcitabine/nab-paclitaxel receive surgically implanted ACT-IOP-003. The device uses iontophoresis to deliver gemcitabine, a DNA synthesis–inhibiting nucleoside analog, directly to the pancreatic tumor region once or twice weekly for 8 weeks to assess local delivery safety and pharmacokinetics.

ClinicalTrials.gov ID: NCT07481383

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic pancreatic, non-small cell lung, HR+/HER2− breast, or triple-negative breast cancer—and colorectal cancer during dose escalation only—undergo screening with the FAP-targeted PET tracer [68Ga]Ga-NNS309. Patients with tracer-avid tumors receive [177Lu]Lu-NNS309, a FAP-targeted radioligand that delivers beta radiation to tumor stroma and nearby cancer cells.

ClinicalTrials.gov ID: NCT06562192